In a Phase 2a clinical trial of Etokimab, a monoclonal antibody targeting IL-33, significant reductions were observed in peripheral blood eosinophil and neutrophil infiltration in the skin of AD patients [13], suggesting that IL-33 contributes to both Th2-mediated eosinophilic infiltration and neutrophilic inflammation. This evidence concerns the gene IL33 and Alzheimer disease.